Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe’s ...

Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place under a court-monitored //process * Lemonaid Health excluded from the deal ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations. Regeneron Pharmaceuticals has announced an agreement to acquire all assets of 23andMe for $256 ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

In a landmark move within the biotech industry, Regeneron Pharmaceuticals has announced its acquisition of 23andMe for $256 million. This deal, emerging from 23andMe's bankruptcy proceedings ...

Regeneron says its $256 million purchase of bankrupt 23andMe’s assets will allow its popular DNA-testing business to carry on — along with a privacy policy allowing customers to have their ...

イラン、ウラン濃縮停止を拒否米との協議決裂を警告 イランは、同国の核問題を巡る米国との協議について、ウラン濃縮の完全停止を米国が要求 ...